CD79A and COVID-19: In addition, estimates of seroconversion in the production of anti-SARS-CoV-2 Spike protein antibodies can vary from 91 to 99% in large studies32,33, where IgA, IgM, and IgG antibodies develop within a few days in infected individuals29,31,34, as observed in this study, where COVID-19 positive patients had a seroconversion of IgM and IgG antibodies, respectively, on the seventh and ninth day after symptom onset.